NCT04831684View on ClinicalTrials.gov

Novel MGluR5 Modulator Effects on Alcohol Drinking and MRI Outcomes

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

April 15, 2026

Study Completion Date

April 22, 2026

Conditions
Alcohol Use Disorder
Interventions
DRUG

Placebo

Participants will be getting placebo for 8 days of dosing.

DRUG

GET73

Participants will be getting GET73 for 8 days of dosing.

Trial Locations (1)

29425

RECRUITING

Charleston Alcohol Research Center, Institute of Psychiatry, Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Medical University of South Carolina

OTHER